Any current/future new fundraising through debt or equity?

There is no mention in the transcript of any current or planned fundraising through debt or equity. The company is focusing on internal CAPEX of around Rs. 120-130 crore this year, primarily for capacity expansion and project modifications, funded through existing resources. No indications or discussions about raising fresh capital via equity or debt instruments were noted during the Q2 FY25 earnings call. The management appears confident about meeting growth and margin targets using their operational cash flows and existing funds. Emphasis is on optimizing capacity utilization, new product in

Any current/future capex/capital investment/strategic investment?

Ongoing CAPEX projects at Unitop and Dahej facilities with about Rs. 60 - Rs. 65 crore already spent. A similar amount expected to be spent over the next 6 months. Projects to be commissioned in Q3, Q4 of the current year and Q1 of next year. Total project budget enhanced by Rs. 18.25 crore, now up to Rs. 146.25 crore due to design modifications. Additional acquisition of 39,101 sqm land adjacent to Dahej facility for future expansion. These investments aimed at serving high-growth segments such as agrochemicals, home & personal care, and specialty chemicals. Expected asset turn of roughly 3x-

Future growth expectations in sales/revenue/volumes?

The company expects low to mid double-digit top-line growth, aiming for around 12%-13% revenue growth for the full year FY25 (Page 9, Page 12). Export sales are a key growth driver, having grown 32% in H1 FY25 and currently constituting about 25% of overall sales. Exports are expected to outpace domestic growth further (Page 3, Page 9). Volume growth is expected in the Textile segment domestically (~6%-7% YoY growth) despite pricing pressure (Page 5). Animal Health & Nutrition business anticipates a much stronger second half, with Q3 and Q4 traditionally being strong quarters, aided by new pro

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects low to mid double-digit top-line growth, targeting around 12%-13% revenue growth for FY25. EBITDA margins are anticipated to remain stable around 13.2%-13.5% in the near term, with potential for improvement as new products scale up and capacity utilization improves. Export business is a key growth driver, with exports growing 32% in H1 FY25 and expected to outpace domestic growth further. Operational improvements and new CAPEX projects (Rs. 60-65 crore spent, similar amount planned) targeting asset turns of 3x-4x will enhance return ratios and future profitability. Margin c

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders in quantitative terms. Discussions highlight growth in exports with a 32% increase in H1 FY25, indicating a healthy demand pipeline internationally. Domestic growth is softer, particularly in home care non-agri and textile exports impacted by geopolitical issues in Bangladesh and Egypt. There is an ongoing focus on expanding export markets including Europe, South America, Middle East, Turkey, Bangladesh, Nepal, and Sri Lanka. New product development internally consumed initially, with plans to offer

IN US

Sale is live|00:00:00left today

Rossari Biotech LtdQ3 FY24Chemicals & Petrochemicals

Rossari Biotech Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹535P/E: 18.8Market Cap: ₹2.8K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→The company expects low to mid double-digit top-line growth, aiming for around 12%-13% revenue growth for the full year FY25 (Page 9, Page 12).
→Export sales are a key growth driver, having grown 32% in H1 FY25 and currently constituting about 25% of overall sales. Exports are expected to outpace domestic growth further (Page 3, Page 9).
→Volume growth is expected in the Textile segment domestically (~6%-7% YoY growth) despite pricing pressure (Page 5).
→Animal Health & Nutrition business anticipates a much stronger second half, with Q3 and Q4 traditionally being strong quarters, aided by new products and infrastructure improvements (Page 6, Page 11).
→New capacities coming online in the next 3-4 months and ongoing CAPEX projects will enhance production, aiming for asset turns of 3x-4x (Page 11, Page 12).
→Improvement in margin and utilization expected as new products and capacities scale up (Page 12).

Margin guidance

Category 3

→The company expects low to mid double-digit top-line growth, targeting around 12%-13% revenue growth for FY25.
→EBITDA margins are anticipated to remain stable around 13.2%-13.5% in the near term, with potential for improvement as new products scale up and capacity utilization improves.
→Export business is a key growth driver, with exports growing 32% in H1 FY25 and expected to outpace domestic growth further.
→Operational improvements and new CAPEX projects (Rs. 60-65 crore spent, similar amount planned) targeting asset turns of 3x-4x will enhance return ratios and future profitability.
→Margin compression due to high freight costs and raw material pricing pressure is expected to normalize over time as freight costs stabilize and pricing adjustments occur.
→Institutional cleaning and Animal Health segments are expected to contribute to future growth, with improved collections and new products anticipated.
→Overall, management is confident about sustaining earnings growth with new initiatives and geographic expansion.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no mention in the transcript of any current or planned fundraising through debt or equity.
→The company is focusing on internal CAPEX of around Rs. 120-130 crore this year, primarily for capacity expansion and project modifications, funded through existing resources.
→No indications or discussions about raising fresh capital via equity or debt instruments were noted during the Q2 FY25 earnings call.
→The management appears confident about meeting growth and margin targets using their operational cash flows and existing funds.
→Emphasis is on optimizing capacity utilization, new product initiatives, and expanding export markets rather than seeking external funding.

Order book

→The transcript does not explicitly mention the current or expected order book or pending orders in quantitative terms.
→Discussions highlight growth in exports with a 32% increase in H1 FY25, indicating a healthy demand pipeline internationally.
→Domestic growth is softer, particularly in home care non-agri and textile exports impacted by geopolitical issues in Bangladesh and Egypt.
→There is an ongoing focus on expanding export markets including Europe, South America, Middle East, Turkey, Bangladesh, Nepal, and Sri Lanka.
→New product development internally consumed initially, with plans to offer to domestic and export markets as capacity expands.
→Management expects improved order inflow from Bangladesh within 1-2 months as banking/payment issues improve.
→Overall growth is expected at 12%-13% top-line for the year, implying a steady order intake to support this forecast.

Capex plans

Yes

→Ongoing CAPEX projects at Unitop and Dahej facilities with about Rs. 60 - Rs. 65 crore already spent.
→A similar amount expected to be spent over the next 6 months.
→Projects to be commissioned in Q3, Q4 of the current year and Q1 of next year.
→Total project budget enhanced by Rs. 18.25 crore, now up to Rs. 146.25 crore due to design modifications.
→Additional acquisition of 39,101 sqm land adjacent to Dahej facility for future expansion.
→These investments aimed at serving high-growth segments such as agrochemicals, home & personal care, and specialty chemicals.
→Expected asset turn of roughly 3x-4x from these investments.
→Establishment of Rossari Biotech Trading FZE in UAE for export market distribution and sales.
→Acquisition of 100% equity in Unistar Thai Company Limited, focusing on specialty chemical manufacturing.

How does Rossari Biotech Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Rossari Biotech Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Rossari Biotech Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio